ProCE Banner Activity

AQUILA: Primary Results From the Phase III Trial of Daratumumab vs Active Monitoring for High-Risk Smoldering Multiple Myeloma

Conference Coverage
Slideset

Primary results from the phase III AQUILA trial for patients with high-risk smoldering multiple myeloma demonstrated that early treatment with subcutaneous daratumumab monotherapy prolonged PFS and OS with a manageable safety profile compared with active monitoring.

Released: December 13, 2024

Expiration: December 12, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation